Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
542 questions in 42 reviews · Skin
current versionsNo studies 542 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
hAMMSC‐CM + vitamin C vs hAMMSC‐CM Secondary outcome: acceptability of treatment · ulceration caused by nerve damage in leprosy Interventions for ulceration and other skin changes caused by nerve damage in leprosy (2019) · Cochrane | no estimate extracted | NR | No studies |
hAMMSC‐CM + vitamin C vs hAMMSC‐CM Secondary outome: cost of intervention · ulceration caused by nerve damage in leprosy Interventions for ulceration and other skin changes caused by nerve damage in leprosy (2019) · Cochrane | no estimate extracted | NR | No studies |
hAMMSC‐CM + vitamin E vs hAMMSC‐CM Primary outcome: prevention of ulcer · ulceration caused by nerve damage in leprosy Interventions for ulceration and other skin changes caused by nerve damage in leprosy (2019) · Cochrane | no estimate extracted | NR | No studies |
hAMMSC‐CM + vitamin E vs hAMMSC‐CM Secondary outcome: quality of life · ulceration caused by nerve damage in leprosy Interventions for ulceration and other skin changes caused by nerve damage in leprosy (2019) · Cochrane | no estimate extracted | NR | No studies |
hAMMSC‐CM + vitamin E vs hAMMSC‐CM Secondary outcome: acceptability of treatment · ulceration caused by nerve damage in leprosy Interventions for ulceration and other skin changes caused by nerve damage in leprosy (2019) · Cochrane | no estimate extracted | NR | No studies |
hAMMSC‐CM + vitamin E vs hAMMSC‐CM Secondary outome: cost of intervention · ulceration caused by nerve damage in leprosy Interventions for ulceration and other skin changes caused by nerve damage in leprosy (2019) · Cochrane | no estimate extracted | NR | No studies |
hAMMSC‐CM + vitamin E vs hAMMSC‐CM + vitamin C Primary outcome: prevention of ulcer · ulceration caused by nerve damage in leprosy Interventions for ulceration and other skin changes caused by nerve damage in leprosy (2019) · Cochrane | no estimate extracted | NR | No studies |
hAMMSC‐CM + vitamin E vs hAMMSC‐CM + vitamin C Secondary outcome: quality of life · ulceration caused by nerve damage in leprosy Interventions for ulceration and other skin changes caused by nerve damage in leprosy (2019) · Cochrane | no estimate extracted | NR | No studies |
hAMMSC‐CM + vitamin E vs hAMMSC‐CM + vitamin C Secondary outcome: acceptability of treatment · ulceration caused by nerve damage in leprosy Interventions for ulceration and other skin changes caused by nerve damage in leprosy (2019) · Cochrane | no estimate extracted | NR | No studies |
Topical timolol vs placebo Proportion of parents who consider their child still has a problem, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Topical timolol vs placebo Proportion of children who consider they still have a problem, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Topical timolol vs placebo Aesthetic appearance as assessed by physician, child, or parent, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral propranolol vs topical timolol Clearance, as assessed by a clinician at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral propranolol vs topical timolol A subjective measure of improvement, as assessed by the parent or child, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral propranolol vs topical timolol Proportion of parents who consider their child still has a problem, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral propranolol vs placebo A subjective measure of improvement, as assessed by the parent or child, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral propranolol vs topical timolol Proportion of children who consider they still have a problem, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral propranolol vs topical timolol Aesthetic appearance as assessed by physician, child, or parent, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral propranolol vs placebo Proportion of parents who consider their child still has a problem, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral propranolol vs placebo Proportion of children who consider they still have a problem, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Oral propranolol vs placebo Aesthetic appearance as assessed by physician, child, or parent, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Topical timolol vs placebo Clearance, as assessed by a clinician at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Topical timolol vs placebo A subjective measure of improvement, as assessed by the parent or child, at any · infantile haemangiomas (strawberry birthmarks) of the skin Interventions for infantile haemangiomas of the skin (2018) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CTLA4 monoclonal antibodies with vs without anti‐PD1 monoclonal antibodies Overall survival · people with cutaneous melanoma Systemic treatments for metastatic cutaneous melanoma (2018) · Cochrane | no estimate extracted | NR | No studies |
Montelukast vs conventional treatment Requirement for corticosteroid (steroid‐sparingeffect) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane | no estimate extracted | NR | No studies |
Montelukast vs conventional treatment Reduction of pruritus · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane | no estimate extracted | NR | No studies |
Montelukast vs conventional treatment Improvement in quality of life · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane | no estimate extracted | NR | No studies |
Montelukast vs conventional treatment Need for emollient use · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane | no estimate extracted | NR | No studies |
Montelukast vs placebo Effect of long‐term control (> 3 months) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane | no estimate extracted | NR | No studies |
Montelukast vs placebo Improvement in quality of life · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane | no estimate extracted | NR | No studies |
Montelukast vs placebo Need for emollient use · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane | no estimate extracted | NR | No studies |
Montelukast vs conventional treatment Effect of long‐term control (> 3 months) · eczema Leukotriene receptor antagonists for eczema (2018) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs placebo Assessment of long‐term morbidity · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
Moxifloxacin vs amoxicillin‐clavulanate Assessment of long‐term morbidity · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
AB103 vs placebo Survival time · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
AB103 vs placebo Assessment of long‐term morbidity · NSTI Interventions for necrotizing soft tissue infections in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% At least 50% reduction in erythema · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% Quality of life measure · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% Relapse · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
R‐salbutamol 0.5% topical cream vs placebo Quality of life measure · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
R‐salbutamol 0.5% topical cream vs placebo Relapse · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Fluocinonide 0.05% vs hydrocortisone 1% At least 50% reduction in erythema · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Tacrolimus 0.1% cream vs placebo Clearing or excellent improvement · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Tacrolimus 0.1% cream vs placebo At least 50% reduction in erythema · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Tacrolimus 0.1% cream vs placebo Quality of life measure · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Tacrolimus 0.1% cream vs placebo Relapse · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Fluocinonide 0.05% vs hydrocortisone 1% Quality of life measure · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Fluocinonide 0.05% vs hydrocortisone 1% Relapse · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |
Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily Quality of life measure · people with discoid lupus erythematosus Drugs for discoid lupus erythematosus (2017) · Cochrane | no estimate extracted | NR | No studies |